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Abstract: BACKGROUND Literature is inconclusive regarding the association between antiplatelet
agents use and outcome after aneurysmal subarachnoid hemorrhage. AIMS To investigate the associ-
ation between clinical outcome and prehemorrhage use in aneurysmal subarachnoid hemorrhage patients
as well as the impact of thrombocyte transfusion on rebleed and clinical outcome. METHODS Data were
collected from prospective databases of two European tertiary reference centers for aneurysmal subarach-
noid hemorrhage patients. Patients were divided into ”antiplatelet-user” and ”non-user” according to the
use of acetylsalicylic acid prior to the hemorrhage. Primary outcome was poor clinical outcome at six
months (Glasgow Outcome Scale score 1-3). Secondary outcomes were in-hospital mortality and impact
of thrombocyte transfusion. RESULTS Of the 1033 patients, 161 (15.6%) were antiplatelet users. The
antiplatelet users were older with higher incidence of cardiovascular risk factors. Antiplatelet use was
associated with poor outcome and in-hospital mortality. After correction for age, sex, World Federation
of Neurosurgical Societies score, infarction and heart disorder, pre-hemorrhage acetylsalicylic acid use was
only associated with poor clinical outcome at six months (adjusted OR 1.80, 95% CI 1.08-3.02). Thrombo-
cyte transfusion was not associated with a reduction in rebleed or poor clinical outcome. CONCLUSION
In this multicenter study, the prehemorrhage acetylsalicylic acid use in aneurysmal subarachnoid hem-
orrhage patients was independently associated with poor clinical outcome at six months. Thrombocyte
transfusion was not associated with the rebleed rate or poor clinical outcome at six months.
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Abstract
Background: Literature is inconclusive regarding the association between antiplatelet agents use and outcome after
aneurysmal subarachnoid hemorrhage.
Aims: To investigate the association between clinical outcome and prehemorrhage use in aneurysmal subarachnoid
hemorrhage patients as well as the impact of thrombocyte transfusion on rebleed and clinical outcome.
Methods: Data were collected from prospective databases of two European tertiary reference centers for aneurysmal
subarachnoid hemorrhage patients. Patients were divided into ‘‘antiplatelet-user’’ and ‘‘non-user’’ according to the use of
acetylsalicylic acid prior to the hemorrhage. Primary outcome was poor clinical outcome at six months (Glasgow
Outcome Scale score 1–3). Secondary outcomes were in-hospital mortality and impact of thrombocyte transfusion.
Results: Of the 1033 patients, 161 (15.6%) were antiplatelet users. The antiplatelet users were older with higher
incidence of cardiovascular risk factors. Antiplatelet use was associated with poor outcome and in-hospital mortality.
After correction for age, sex, World Federation of Neurosurgical Societies score, infarction and heart disorder, pre-
hemorrhage acetylsalicylic acid use was only associated with poor clinical outcome at six months (adjusted OR 1.80, 95%
CI 1.08–3.02). Thrombocyte transfusion was not associated with a reduction in rebleed or poor clinical outcome.
Conclusion: In this multicenter study, the prehemorrhage acetylsalicylic acid use in aneurysmal subarachnoid hemor-
rhage patients was independently associated with poor clinical outcome at six months. Thrombocyte transfusion was not
associated with the rebleed rate or poor clinical outcome at six months.
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Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) is a
potentially fatal disease, carrying a six months’ case
fatality rate of 55–60%1–3 and more than one third of
survivors have severe disability.4 Many complications
such as rebleed, delayed cerebral ischemia (DCI) and
hydrocephalus are multifactorial and negatively affect
clinical outcome.3
Antiplatelet agents are used for secondary preven-
tion of various cardiovascular and cerebrovascular
events in a wide range of high-risk patients,5–7 and
their use has been associated with a lower incidence
of aSAH. It is hypothesized that this might be mediated
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by a protective effect against chronic inflammation and
subsequent aneurysm wall degeneration.8–10 However,
antiplatelet use has also been related to early rebleeds,
treatment-related complications and worse outcome
after aSAH.11–13
Decision-making regarding the management of
patients with prehemorrhage antiplatelet agents use is
mainly based on inconsistent results and nonsignificant
findings.11–15 As no evidence-based recommendations
regarding the management of prehemorrhage antiplate-
let use in aSAH patients exist, the decision to stop anti-
platelet medication is often associated with the presence
or absence of local guidelines.16 One recent study17
found an association between thrombocyte transfusion
and poor clinical outcome after six months in patients
with aSAH and this needs further clarification.
Aims
The main purpose of this study was to investigate the
influence of prehemorrhage antiplatelet use on the clin-
ical outcome after aSAH, considering confounding fac-
tors. Additionally, we studied potential effects of




Patients were retrieved from prospectively collected
databases, including patients at the Department of
Neurosurgery of the University Hospital Zurich treated
between January 2005 and December 2016 and the
Academic University Medical Center Amsterdam trea-
ted between December 2011 and December 2015. Both
hospitals are high-volume tertiary reference centers for
the treatment of aSAH. The research ethics board of
the Canton Zurich, Switzerland approved this study.
Patient characteristics
We included patients older than 18 years of age who
had confirmed aSAH on admission computed tomog-
raphy (CT) imaging or positive lumbar puncture and a
proven aneurysm in either computed tomography angi-
ography or digital subtraction angiography. Subjects
meeting any of the below-mentioned criteria were
excluded from this study: patients with non-aneurysmal
SAH, perimesencephalic hemorrhage (according to the
previous published definition18) as well as patients with
traumatic SAH.
Patients were divided into the groups ‘‘antiplatelet-
user’’ and ‘‘non-user’’ according to the use of acetylsali-
cylic acid (ASA) prior to the hemorrhage. Because ASA
in combination with other antiplatelet agents was
assumed to be associated with a worse outcome than
ASA alone, the outcome of this patient group was
explored prior to including them to the ‘‘antiplatelet-
user’’ cohort and excluded if they showed a significant
difference in outcome. Patients with anticoagulation
therapy were excluded on beforehand. ASA was
stopped in all patients immediately after the radio-
logical diagnosis of aSAH.
The patients’ characteristics, clinical and radio-
logical data as well as clinical outcome data were col-
lected by trained staff and verified by an attending
vascular neurosurgeon. Furthermore, we collected the
treatment modalities, in-hospital complications as well
as cardiovascular risk factors (smoking, hypertension,
hypercholesterolemia, heart disorder, diabetes). Heart
disorders were characterized according to World Heart
Federation.19 The initial clinical severity and radio-
logical grade were assessed using the World
Federation of Neurosurgical Societies (WFNS) grade
and the Fisher score, respectively. We dichotomized
the WFNS into WFNS 1–3 and 4–5 and the Fisher
score into 3 vs. 1, 2 and 4.20,21
In-hospital complications including hydrocephalus
and its treatment modality (external ventricular drain-
age (EVD) or ventriculoperitoneal (VP) shunt place-
ment), rebleed, occurrence of DCI and infarction were
registered for outcome comparison between groups.
Only patients with radiologically confirmed rebleed
were included in the rebleed group. DCI was defined
according to Vergouwen et al.22 Only confirmed new
ischemic lesions on follow-up imaging (CT and/or mag-
netic resonance imaging), which were not seen immedi-
ately after the aneurysm excluding procedure, were
included in the analysis. The clinical outcome was eval-
uated using the Glasgow outcome scale (GOS), with
GOS 1 (death) at initial hospital admission and six-
months’ follow-up, and poor (GOS 1–3) and favorable
(GOS 4–5) outcome at six-months’ follow-up.
Data analysis
Prior to data analysis, we explored the outcome of
patients with ASA in combination with other antiplate-
let agents in relation patients with ASA alone. As all
patients with double antiplatelet medications had a
poor outcome, which was significantly different from
the group with ASA alone, we decided to exclude
these patients from further analysis.
Baseline characteristics, disease-associated complica-
tions, treatment and outcome factors were compared
between ‘‘antiplatelet users’’ and ‘‘non-users.’’
Continuous variables are presented as mean with its
standard deviation (SD) if normally distributed and
as median with its interquartile range if not.
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Categorical variables are presented as count and per-
centages and are dichotomized to relevant clinical cut-
off points. Group differences are calculated using the
Chi-square test and Student’s t-test. A two-sided
p-value< 0.05 is considered significant.
Crude and adjusted odd ratios (OR) were calculated
for prehemorrhage antiplatelet use in relation to poor
outcome, in-hospital mortality and mortality at six
months with logistic regression analysis. If the change
between crude and adjusted OR was >10%, the corres-
ponding parameter for which the stratification was
performed was considered as a confounder.
A multivariable logistic regression analysis was per-
formed, adjusting for confounders. In the antiplatelet
user group, the impact of thrombocyte transfusion on
rebleed and poor outcome was calculated using a Chi-
square test. Analysis was performed with STATA ver-
sion 16.0 (StataCorp, Stata Statistical Software:
Release 16, College Station, TX) software.
Results
Baseline characteristics and treatment modalities
A total of 1123 patients were eligible for the study.
Ninety patients (8.0%) with missing outcome data at
six months were excluded from the analysis. The study
flowchart is given in Figure 1. The remaining 1033
patients consisted of 692 (67%) women and 161
(15.6%) used ASA prior to the onset of aSAH
(Table 1). Antiplatelet users were older compared to
non-users with a higher prevalence of hypertension,
diabetes, heart disorder and hypercholesterolemia
(Table 1). No difference was seen in clinical status on
admission, nor in the Fisher score between both groups
(Table 1).
Outcome
The proportion of poor outcome at six months’ follow-
up was higher in the antiplatelet group compared to the
non-user group (OR 2.45, 95% CI 1.74–3.47)
(Supplementary Table 1). A significant increase of in-
hospital mortality as well as increase in mortality at six
months was observed in the antiplatelet user group (OR
1.94, 95% CI 1.34–2.82 and OR 1.87, 95% CI 1.28–
2.73, respectively) (Supplementary Tables 2 and 3). We
did not find a difference in rebleed rate, DCI, infarc-
tion, rate of hydrocephalus, need for urgent EVD or
VP-shunt dependency (Table 2). In the antiplatelet user
group, five patients were diagnosed with NSTEMI,
most likely due to the aSAH itself.
Risk factors and poor outcome at six months
The following parameters were assessed as confounders
and are included into the multivariable analysis
(Supplementary file 1, 2 and 3): age, sex, WFNS
Figure 1. Study flow chart. Between January 2005 and December 2016, 791 patients with aSAH and prehemorrhage antiplatelet
use were treated at the Department of Neurosurgery of the University Hospital Zurich and 332 patients between December
2011 and December 2015 at the Department of Neurosurgery of the Academic University Medical Center Amsterdam.
Cumulative, 1123 patients with aSAH and prehemorrhage acetylsalicylic acid use were available for inclusion in this prospective
cohort study. Ninety patients with missing six-month clinical outcome data were excluded from the study. In the final analysis,
1033 patients were included. aSAH: aneurysmal subarachnoid hemorrhage.
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score, infarction and heart disorder for poor outcome
and age, sex, infarction, heart disorder, hypercholester-
olemia and smoking for in-hospital and six months’
mortality. Antiplatelet use was independently asso-
ciated with poor outcome at six months (adjusted OR
1.80, 95% CI 1.08–3.02), whereas it was neither asso-
ciated with in-hospital mortality (adjusted OR 0.97,
95% CI 0.56–1.66) nor with mortality at six months
(adjusted OR 0.89, 95% CI 0.51–1.53).
Thrombocyte transfusion
Of the 161 patients with a history of prehemorrhage
ASA use, 67 (41.6%) received a thrombocyte transfu-
sion. Patients who received a thrombocyte transfusion
after the rebleeding event (n¼ 2) were not included in the
transfusion group. The rate of rebleed was higher in
patients who did not receive a thrombocyte transfusion;
however, this difference was not significant (transfusion
vs. no transfusion: 5 (7.7%) vs. 17 (17.7%), p¼ 0.07;
Table 3). There was no difference in poor outcome
between patients receiving thrombocyte transfusion
and those who did not (transfusion vs. no transfusion:
37 (55.2%) vs. 53 (56.4%), p¼ 0.83; Table 3).
Discussion
In this multicenter study, the prehemorrhage ASA use
in aSAH patients was identified as an independent risk
factor for poor outcome (defined as GOS 1–3) at six
Table 1. Baseline characteristics of 1033 patients with aneurysmal subarachnoid hemorrhage. [AQ1]
Antiplatelet users (n¼ 161) Nonusers (n¼ 872) p-value
Age (mean SD) 63.6 12.5 54.4 12.3 <0.001
Sex, female, n (%) 109 (67.7) 583 (66.9) 0.83
Smoking, n (%) 75 (46.6) 416 (50.7) 0.36
Hypertension, n (%) 94 (58.4) 263 (30.2) <0.001
Hypercholesterolemia, n (%) 42 (26.1) 63 (7.2) <0.001
Heart disorder, n (%) 55 (34.2) 53 (6.1) <0.001
Diabetes, n (%) 14 (8.7) 28 (3.2) 0.001
Fisher score 0.74
¼ 1, n (%) 6 (3.7) 32 (3.7)
¼ 2, n (%) 4 (2.5) 43 (4.9)
¼ 3, n (%) 30 (18.6) 229 (26.3)
¼ 4, n (%) 121 (75.2) 568 (65.1)
WFNS 0.43
¼ 1, n (%) 57 (33.7) 287 (32.9)
¼ 2, n (%) 35 (21.5) 222 (25.5)
¼ 3, n (%) 13 (8.1) 98 (11.2)
¼ 4, n (%) 29 (18.0) 136 (15.6)
¼ 5, n (%) 27 (16.8) 129 (14.8)
Aneurysm clipping, n (%) 67 (41.6) 357 (40.9) 0.87
Aneurysm coiling, n (%) 72 (44.7) 448 (51.4) 0.12
No treatment, n (%) 22 (13.7) 67 (7.7) 0.14
n: number; SD: standard deviation; WFNS: World Federation of Neurological Surgeons.
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months after aSAH. Thrombocyte transfusion in the
subgroup of antiplatelet users had no significant
impact on the rate of rebleed or patient outcome at
six months.
Impact of prehemorrhage ASA use on clinical
outcome after aSAH
Previous studies have reported conflicting results
regarding the impact of prehemorrhage antiplatelet
use and patients’ outcome and some did not find an
association between ASA use (other antiplatelet or
anticoagulant agents were excluded) and poor out-
come.12 Our data show a significantly higher propor-
tion of poor outcome and in-hospital mortality in the
ASA users. This cannot be explained by a higher
rebleed rate, nor by a more severe hemorrhage pattern.
Our finding that prehemorrhage antiplatelet use is an
independent risk factor for poor outcome has
previously been suggested.11 Kato et al. reported the
influence of antiplatelet agents before the onset of hem-
orrhage and concluded that antiplatelet agents was sig-
nificantly associated with worse outcome in patients of
70–79 years.11
Cerebrovascular and cardiovascular effects of
antiplatelet agents
Antiplatelet agents, especially ASA, have well-known
positive effects on reducing the risk of cardiovascu-
lar23,24 and cerebrovascular25,26 diseases. Moreover,
several recent studies suggested that ASA may decrease
the risk of growth and rupture of cerebral aneur-
ysms.8,10,27 After rupture, however, ASA is possibly
associated with an increased risk of recurrent bleeding
before treatment28 and ASA given after aneurysm
treatment in aSAH does not improve clinical
outcome.29
Table 2. Clinical outcome, mortality and in-hospital complications and their treatment modalities of 1033 patients with aneurysmal
subarachnoid hemorrhage.
Antiplatelet users (n ¼161) Nonusers (n¼ 872) p-value
Poor outcome (GOS 1–3), n (%) 90 (55.9.0) 297 (34.1) <0.001
In-hospital mortality, n (%) 49 (30.4) 165 (18.9) 0.001
Mortality at six months, n (%) 50 (31.1) 181 (20.8) 0.004
Rebleed, n (%) 22 (13.7) 102 (11.7) 0.49
Delayed cerebral ischemia, n (%) 32 (19.9) 219 (25.1) 0.16
Infarction (not post-treatment)a, n (%) 26 (22.4) 129 (21.0) 0.29
Hydrocephalus, n (%) 110 (68.3) 539 (61.8) 0.12
Urgent external ventricular drain, n (%) 91 (56.5) 453 (51.9) 0.29
Ventriculoperitoneal-shunt dependency, n (%) 41 (25.5) 178 (20.4) 0.15
All p-values were calculated using a Chi-square test. GOS: Glasgow Outcome Scale; n: number.
aFor n¼735 (antiplatelet users: 122; nonusers: 613).




Rebleed rate, n (%) 5/65a (7.7%) 17/96 (17.7%) 0.07
Poor outcome, n (%) 37/67 (55.2%) 53/94 (56.4%) 0.83
GOS: Glasgow Outcome Scale; n: number.
aGiven the fact that we wanted to address aneurysm rebleeding cases, the two patients, who received a thrombocyte transfusion after the rebleeding
event were for this crosstab calculation included in the non-transfusion group.
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One study showed that long-term ASA and anti-
coagulant use among patients with aSAH and endovas-
cular aneurysm treatment was not associated with
increased mortality or complication rates.14 Another
study suggested a potential beneficial effect of ASA in
the setting of intracranial aneurysms by weighing the
risk of rupture against its potential adverse effects on
hemorrhage severity. Those findings contradict with
our findings, however, both studies drew their conclu-
sions on a lower number of patients.
A possible reason for the increased risk of poor out-
come in antiplatelet users could be the inhibition of
platelet activation. This can theoretically exacerbate
the initial hemorrhage and the use of antiplatelet
drugs can complicate surgical procedures.11 However,
in our cohort we could not confirm this hypothesis as
we did not find a significant difference in rebleed rate.
Furthermore, higher age and higher proportion of
heart disorder in antiplatelet users could have influ-
enced the outcome. However, when we corrected for
these confounders, antiplatelet use remained associated
with poor outcome. This is opposing to findings by
Bruder et al.30 who in the matched-pair analysis did
not find a different outcome as evaluated by modified
Rankin scale between patients with continuous ASA
and patients without ASA.
Due to the aging population and rising number of
patients with cardiovascular or neurovascular disease,
there is an increasing number of patients taking anti-
platelet and anticoagulative drugs.31 A previous study
showed a significant increase in the rate of patients with
continuous ASA use at the time of aneurysm rupture
over the observed period of 15 years.30 This emphasizes
the importance of guidelines and treatment recommen-
dations in this patient group. A recently conducted
survey shows that there is significant variability in the
management of patients with aSAH and antiplatelet
use before admission.16 Departmental guidelines are
only present in 32% and have an impact on decision-
making to stop the antiplatelet agent and/or transfuse
thrombocytes.16
Impact of thrombocyte transfusion on outcome
after aSAH
Thrombocyte transfusion in patients with spontaneous
intracerebral hemorrhage has been investigated in sev-
eral studies but patients with aSAH were
excluded.27,32,33 Results of the randomized controlled
PATCH trial34 showed a higher case fatality rate
when thrombocytes were acutely transfused in non-sur-
gically treated patients taking antiplatelet therapy prior
to intracerebral hemorrhage. Although patients with
aSAH were not included in the study, it opened the
discussion about whether thrombocyte transfusion in
aSAH could be harmful to patients instead of benefi-
cial. In a recent consecutive series of 364 patients with
aSAH, 38 patients used antiplatelet therapy prior to
admission and underwent thrombocyte transfusion
during hospital admission; those patients showed
poor clinical outcome at six months after correcting
for confounders.17 Based on the available data, how-
ever, no firm recommendation regarding thrombocyte
transfusion in patients with aSAH can be given so
future research in larger cohorts are needed.
No difference in poor outcome at six months
between the patients with and without transfusion
was seen. So, based on the findings of our study,
thrombocyte transfusion does not seem to be harmful
in aSAH patients. On the contrary, a recent study by
Post et al. found an association between thrombocyte
transfusion and poor clinical outcome at six months.17
Based on current very limited findings, we still do not
know the balance between risk and benefit of thrombo-
cyte transfusion in patients with aSAH and prehemor-
rhage antiplatelet use. A pooled analysis of data from
both cohort and larger international (randomized) stu-
dies could clarify this issue.
Limitations
We performed a retrospective analysis of prospectively
collected data and some data were collected retrospect-
ively. This way of data collection could have induced
information bias. Moreover, information bias could
also have been introduced by failure in recalling
whether the patient used ASA by the next of kin. To
minimize the information bias, the validated outcome
measurements were collected by physicians and
research nurses who were all trained for performing
outcome assessment. Since studies have found that
25% of all patients with aSAH die before reaching hos-
pital, our data are not generalizable to the complete
aSAH population including non-hospitalized
patients.35 We did not collect data on duration of
ASA use before the hemorrhage, neither did we assess
thrombocyte aggregation status. Finally, the timing of
thrombocyte transfusion was not assessed in the cur-
rent cohort.
Conclusion
In this multicenter study, the use of ASA before onset
of aSAH was found to be independently associated
with poor outcome (defined as GOS 1–3) at six
months. Prehemorrhage ASA use is not associated
with a higher in-hospital or six months’ mortality
rate. Thrombocyte transfusion had no impact on the
rebleed rate or poor outcome at six months. Future
studies are necessary to assess the optimal management
International Journal of Stroke, 0(0)
6 International Journal of Stroke 0(0)
of patients who use ASA with or without other anti-
platelet agents before the onset of aSAH.
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